On June 15, Twist Bioscience rose 5.59% in regular trading, trading at $80.35/share, with turnover of $51.52 million.

On the news front, Canaccord Genuity issued a buy rating on Twist Bioscience with a target price of $90, implying approximately 12% upside from the current price level. According to FactSet data, the stock carries an average analyst rating of buy with a mean target price of $73.12. The Canaccord Genuity target significantly exceeds the market consensus level, providing a clear near-term catalyst for the stock.

Twist Bioscience is a synthetic biology platform company that has developed a disruptive silicon-based DNA synthesis technology. The company serves customers across healthcare, food and agriculture, industrial chemicals, academic research, and data storage markets. The company reported its most recent quarterly earnings on May 4, posting an EPS of -$0.62. Despite ongoing losses, the elevated target price from Canaccord Genuity reflects confidence in the company's long-term growth trajectory and commercial potential across its diversified end markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)